Urinary Biomarkers of Brain Diseases

Genomics, Proteomics and Bioinformatics

Volumn 13, Issue 6, 2015, Pages 345-354

  An, Manxia ^a   Gao, Youhe ^a,b  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b BEIJING NORMAL UNIVERSITY   (China)

Author keywords

Biomarkers; Brain diseases; Metabolomics; Proteomics; Urine

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

ALZHEIMER DISEASE; AUTISM; BIPOLAR DISORDER; BLOOD; BRAIN DISEASE; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DISEASE COURSE; HUMAN; MAJOR DEPRESSION; METABOLOME; METABOLOMICS; MULTIPLE SCLEROSIS; NEUROENDOCRINE TUMOR; PARKINSON DISEASE; PRION DISEASE; PROTEOMICS; REVIEW; SCHIZOPHRENIA; TRAUMATIC BRAIN INJURY; URINALYSIS; BRAIN DISEASES; BRAIN INJURIES; METABOLISM; NEUROENDOCRINE TUMORS; PHYSIOLOGY; URINE;

BIOMARKERS; BRAIN DISEASES; BRAIN INJURIES; HUMANS; METABOLOME; NEUROENDOCRINE TUMORS; PROTEOME;

EID: 84957440929     PISSN: 16720229     EISSN: 22103244     Source Type: Journal    
DOI: 10.1016/j.gpb.2015.08.005     Document Type: Review

References (73)

1. Wu J., Gao Y. Physiological conditions can be reflected in human urine proteome and metabolome. Expert Rev Proteomics 2015, 12:623-636.
2. Gao Y. Urine-an untapped goldmine for biomarker discovery?. Sci China Life Sci 2013, 56:1145-1146.
3. Gao Y. Roadmap to the urine biomarker era. MOJ Proteomics Bioinform 2014, 1:00005.
4. Schanstra J.P., Mischak H. Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatr Nephrol 2015, 30:713-725.
5. Pejcic M., Stojnev S., Stefanovic V. Urinary proteomics-a tool for biomarker discovery. Ren Fail 2010, 32:259-268.
6. Jove M., Portero-Otin M., Naudi A., Ferrer I., Pamplona R. Metabolomics of human brain aging and age-related neurodegenerative diseases. J Neuropathol Exp Neurol 2014, 73:640-657.
7. Miao Y., Liao J.K. Potential serum biomarkers in the pathophysiological processes of stroke. Expert Rev Neurother 2014, 14:173-185.
8. Lerma E.V. Approach to the patient with renal disease. Prim Care 2008, 35:183-194.
9. Haubitz M., Wittke S., Weissinger E.M., Walden M., Rupprecht H.D., Floege J., et al. Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 2005, 67:2313-2320.
10. Wu D.L., Zhang W.H., Wang W.J., Jing S.B., Xu Y.M. Proteomic evaluation of urine from renal cell carcinoma using SELDI-TOF-MS and tree analysis pattern. Technol Cancer Res Treat 2008, 7:155-160.
11. Quintana L.F., Sole-Gonzalez A., Kalko S.G., Banon-Maneus E., Sole M., Diekmann F., et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 2009, 20:428-435.
12. Seetho I.W., Siwy J., Albalat A., Mullen W., Mischak H., Parker R.J., et al. Urinary proteomics in obstructive sleep apnoea and obesity. Eur J Clin Invest 2014, 44:1104-1115.
13. Carty D.M., Siwy J., Brennand J.E., Zürbig P., Mullen W., Franke J., et al. Urinary proteomics for prediction of preeclampsia. Hypertension 2011, 57:561-569.
14. Delles C., Diez J., Dominiczak A.F. Urinary proteomics in cardiovascular disease: achievements, limits and hopes. Proteomics Clin Appl 2011, 5:222-232.
15. Ng D., Salim A., Liu Y., Zou L., Xu F., Huang S., et al. A metabolomic study of low estimated GFR in non-proteinuric type 2 diabetes mellitus. Diabetologia 2012, 55:499-508.
16. Xie G., Zheng X., Qi X., Cao Y., Chi Y., Su M., et al. Metabonomic evaluation of melamine-induced acute renal toxicity in rats. J Proteome Res 2010, 9:125-133.
17. Kang S.M., Park J.C., Shin M.J., Lee H., Oh J., Ryu do H., et al. (1)H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clin Biochem 2011, 44:293-299.
18. Shariff M.I., Ladep N.G., Cox I.J., Williams H.R., Okeke E., Malu A., et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J Proteome Res 2010, 9:1096-1103.
19. Slupsky C.M., Steed H., Wells T.H., Dabbs K., Schepansky A., Capstick V., et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 2010, 16:5835-5841.
20. Hill R.J., Chopra P., Richardi T. Rethinking the psychogenic model of complex regional pain syndrome: somatoform disorders and complex regional pain syndrome. Anesth Pain Med 2012, 2:54.
21. Fava M., Kendler K.S. Major depressive disorder. Neuron 2000, 28:335-341.
22. Wang Y., Chen J., Chen L., Zheng P., Xu H.B., Lu J., et al. Urinary peptidomics identifies potential biomarkers for major depressive disorder. Psychiatry Res 2014, 217:25-33.
23. Puchades M., Hansson S.F., Nilsson C.L., Andreasen N., Blennow K., Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003, 118:140-146.
24. Huang J.T., Wang L., Prabakaran S., Wengenroth M., Lockstone H.E., Koethe D., et al. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 2008, 13:1118-1128.
25. Zheng P., Wang Y., Chen L., Yang D., Meng H., Zhou D., et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol Cell Proteomics 2013, 12:207-214.
26. Zheng P., Chen J.J., Huang T., Wang M.J., Wang Y., Dong M.X., et al. A novel urinary metabolite signature for diagnosing major depressive disorder. J Proteome Res 2013, 12:5904-5911.
27. Merikangas K.R., Jin R., He J.P., Kessler R.C., Lee S., Sampson N.A., et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011, 68:241-251.
28. Muller-Oerlinghausen B., Berghofer A., Bauer M. Bipolar disorder. Lancet 2002, 359:241-247.
29. Chen J.J., Liu Z., Fan S.H., Yang D.Y., Zheng P., Shao W.H., et al. Combined application of NMR- and GC-MS-based metabonomics yields a superior urinary biomarker panel for bipolar disorder. Sci Rep 2014, 4:5855.
30. Xu X.J., Zheng P., Ren G.P., Liu M.L., Mu J., Guo J., et al. 2,4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder. Mol BioSyst 2014, 10:813-819.
31. Zheng P., Wei Y.-D., Yao G.-E., Ren G.-P., Guo J., Zhou C.-J., et al. Novel urinary biomarkers for diagnosing bipolar disorder. Metabolomics 2013, 9:800-808.
32. Grigoroiu-Serbanescu M., Nothen M.M., Ohlraun S., Propping P., Maier W., Wickramaratne P., et al. Family history influences age of onset in bipolar I disorder in females but not in males. Am J Med Genet B Neuropsychiatr Genet 2005, 133B:6-11.
33. Mackay C.E., Roddick E., Barrick T.R., Lloyd A.J., Roberts N., Crow T.J., et al. Sex dependence of brain size and shape in bipolar disorder: an exploratory study. Bipolar Disord 2010, 12:306-311.
34. Chen J.J., Huang H., Zhao L.B., Zhou D.Z., Yang Y.T., Zheng P., et al. Sex-specific urinary biomarkers for diagnosing bipolar disorder. PLoS One 2014, 9:e115221.
35. Muhle R., Trentacoste S.V., Rapin I. The genetics of autism. Pediatrics 2004, 113:e472-e486.
36. Yap I.K., Angley M., Veselkov K.A., Holmes E., Lindon J.C., Nicholson J.K. Urinary metabolic phenotyping differentiates children with autism from their unaffected siblings and age-matched controls. J Proteome Res 2010, 9:2996-3004.
37. Parracho H.M., Bingham M.O., Gibson G.R., McCartney A.L. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. J Med Microbiol 2005, 54:987-991.
38. Noto A., Fanos V., Barberini L., Grapov D., Fattuoni C., Zaffanello M., et al. The urinary metabolomics profile of an Italian autistic children population and their unaffected siblings. J Matern Fetal Neonatal Med 2014, 27:46-52.
39. Shaw W. Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an abnormal phenylalanine metabolite of Clostridia spp. in the gastrointestinal tract, in urine samples from patients with autism and schizophrenia. Nutr Neurosci 2010, 13:135-143.
40. Dyck L.E., Kazakoff C.W., Dourish C.T. The role of catecholamines, 5-hydroxytryptamine and m-tyramine in the behavioural effects of m-tyrosine in the rat. Eur J Pharmacol 1982, 84:139-149.
41. Kaluzna-Czaplinska J., Zurawicz E., Struck W., Markuszewski M. Identification of organic acids as potential biomarkers in the urine of autistic children using gas chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2014, 966:70-76.
42. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999, 46:729-739.
43. Cai H.L., Li H.D., Yan X.Z., Sun B., Zhang Q., Yan M., et al. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res 2012, 11:4338-4350.
44. Yang J., Chen T., Sun L., Zhao Z., Qi X., Zhou K., et al. Potential metabolite markers of schizophrenia. Mol Psychiatry 2013, 18:67-78.
45. Donnan G.A., Fisher M., Macleod M., Davis S.M. Stroke. Lancet 2008, 371:1612-1623.
46. Latchaw R.E., Alberts M.J., Lev M.H., Connors J.J., Harbaugh R.E., Higashida R.T., et al. Recommendations for imaging of acute ischemic stroke: a scientific statement from the American Heart Association. Stroke 2009, 40:3646-3678.
47. Chalela J.A., Kidwell C.S., Nentwich L.M., Luby M., Butman J.A., Demchuk A.M., et al. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet 2007, 369:293-298.
48. Sironi L., Tremoli E., Miller I., Guerrini U., Calvio A.M., Eberini I., et al. Acute-phase proteins before cerebral ischemia in stroke-prone rats: identification by proteomics. Stroke 2001, 32:753-760.
49. Dawson J., Walters M., Delles C., Mischak H., Mullen W. Urinary proteomics to support diagnosis of stroke. PLoS One 2012, 7:e35879.
50. Jung J.Y., Lee H.S., Kang D.G., Kim N.S., Cha M.H., Bang O.S., et al. 1H-NMR-based metabolomics study of cerebral infarction. Stroke 2011, 42:1282-1288.
51. Homocysteine Studies C Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002, 288:2015-2022.
52. Mucke L. Neuroscience: Alzheimer's disease. Nature 2009, 461:895-897.
53. Lovestone S. Searching for biomarkers in neurodegeneration. Nat Med 2010, 16:1371-1372.
54. Fukuhara K., Ohno A., Ota Y., Senoo Y., Maekawa K., Okuda H., et al. NMR-based metabolomics of urine in a mouse model of Alzheimer's disease: identification of oxidative stress biomarkers. J Clin Biochem Nutr 2013, 52:133-138.
55. Peng J., Guo K., Xia J., Zhou J., Yang J., Westaway D., et al. Development of isotope labeling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease. J Proteome Res 2014, 13:4457-4469.
56. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 1998, 339:1044-1053.
57. Luan H., Liu L.F., Meng N., Tang Z., Chua K.K., Chen L.L., et al. LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease. J Proteome Res 2015, 14:467-478.
58. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359:1221-1231.
59. Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998, 339:285-291.
60. Singh V., Stingl C., Stoop M.P., Zeneyedpour L., Neuteboom R.F., Smitt P.S., et al. Proteomics urine analysis of pregnant women suffering from multiple sclerosis. J Proteome Res 2015, 14:2065-2073.
61. Prusiner S.B. Molecular biology of prion diseases. Science 1991, 252:1515-1522.
62. Plews M., Lamoureux L., Simon S.L., Graham C., Ruddat V., Czub S., et al. Factors affecting the accuracy of urine-based biomarkers of BSE. Proteome Sci 2011, 9:6.
63. Lamoureux L., Simon S.L., Plews M., Ruddat V., Brunet S., Graham C., et al. Urine proteins identified by two-dimensional differential gel electrophoresis facilitate the differential diagnoses of scrapie. PLoS One 2013, 8:e64044.
64. Ferone G., Mollo M.R., Thomason H.A., Antonini D., Zhou H., Ambrosio R., et al. P63 control of desmosome gene expression and adhesion is compromised in AEC syndrome. Hum Mol Genet 2013, 22:531-543.
65. Li X., Masliah E., Reixach N., Buxbaum J.N. Neuronal production of transthyretin in human and murine Alzheimer's disease: is it protective?. J Neurosci 2011, 31:12483-12490.
66. Kuhr F., Lowry J., Zhang Y., Brovkovych V., Skidgel R.A. Differential regulation of inducible and endothelial nitric oxide synthase by kinin B1 and B2 receptors. Neuropeptides 2010, 44:145-154.
67. Massironi S., Sciola V., Peracchi M., Ciafardini C., Spampatti M.P., Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol 2008, 14:5377-5384.
68. Kinross J.M., Drymousis P., Jimenez B., Frilling A. Metabonomic profiling: a novel approach in neuroendocrine neoplasias. Surgery 2013, 154:1185-1192. discussion 1192-3.
69. Ghajar J. Traumatic brain injury. Lancet 2000, 356:923-929.
70. Ottens A.K., Stafflinger J.E., Griffin H.E., Kunz R.D., Cifu D.X., Niemeier J.P. Post-acute brain injury urinary signature: a new resource for molecular diagnostics. J Neurotrauma 2014, 31:782-788.
71. Li X., Zhao M., Li M., Jia L., Gao Y. Effects of three commonly-used diuretics on the urinary proteome. Genomics Proteomics Bioinformatics 2014, 12:120-126.
72. Andersen M.B., Kristensen M., Manach C., Pujos-Guillot E., Poulsen S.K., Larsen T.M., et al. Discovery and validation of urinary exposure markers for different plant foods by untargeted metabolomics. Anal Bioanal Chem 2014, 406:1829-1844.
73. Airoldi L., Magagnotti C., Iannuzzi A.R., Marelli C., Bagnati R., Pastorelli R., et al. Effects of cigarette smoking on the human urinary proteome. Biochem Biophys Res Commun 2009, 381:397-402.